9 Most Undervalued Pharma Stocks to Buy Right Now

Page 8 of 8

1. Pfizer Inc. (NYSE:PFE)

Forward P/E Ratio: 8.53

Price Target Upside: 12.19%

Pfizer Inc (NYSE:PFE) tops our list for being one of the most undervalued pharmaceutical stocks.

On Friday, December 12, 2025, The Fly reported that Morgan Stanley maintained its Hold (Equal‑Weight) rating on PFE., while lowering the price target to $28 from a prior estimate of $32. The move reflects a neutral outlook on the company’s near-term valuation and growth prospects amid ongoing market pressures.

The rating followed Pfizer Inc (NYSE:PFE)’s announcement on Wednesday, December 10, 2025, of positive Phase 3 clinical results for its drug TUKYSA (tucatinib). The data showed that adding TUKYSA to first-line maintenance therapy extended median progression-free survival by over eight months in patients with HER2-positive metastatic breast cancer. Acquired through PFE’s Seagen acquisition, TUKYSA highlights the value of the company’s pipeline and acquired assets in offsetting declining COVID-19-related revenues.

Pfizer Inc (NYSE:PFE) is a massive American multinational pharmaceutical and biotechnology corporation. It is known for developing and producing medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. 9 Most Undervalued Pharma Stocks to Buy Right Now is originally published on Insider Monkey. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 8 of 8